Literature DB >> 7745754

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

F Breitburd1, R Kirnbauer, N L Hubbert, B Nonnenmacher, C Trin-Dinh-Desmarquet, G Orth, J T Schiller, D R Lowy.   

Abstract

We tested the ability of vaccination with virus-like particles (VLPs) to protect domestic rabbits against papillomas induced by the cottontail rabbit papillomavirus (CRPV). A recombinant baculovirus system that expressed only the L1 major papillomavirus structural protein or L1 plus the minor L2 protein was used in insect cells as the source of VLPs. Groups of 10 rabbits were immunized with native or denatured VLPs from CRPV or type 1 bovine papillomavirus by using Freund's adjuvant. Alum was used as the adjuvant for an additional group immunized with CRPV L1-L2 VLPs. Animals were challenged with 5 x 10(10) and 2 x 10(11) particles on opposing flanks. No protection was seen in rabbits immunized with native or denatured bovine papillomavirus L1-L2 or with denatured CRPV L1-L2. In these groups, the lower and higher challenge doses resulted in 27 of 30 animals with extensive papillomas, with each of the remaining animals having a smaller number of persistent papillomas. Progression to carcinoma developed in 20 rabbits. Animals inoculated with native CRPV VLPs composed of L1 alone or L1-L2 developed many fewer lesions; the lower and higher challenge doses resulted in 17 of 29 and 5 of 29 rabbits, respectively, with no lesions, and the remainder developed only one to eight papillomas, which all regressed except for those on 1 rabbit. None developed cancer within 1 year of infection. Rabbits vaccinated with native CRPV VLPs developed high-titer antibodies in an enzyme-linked immunosorbent assay based on native VLPs, and passive transfer of serum or immunoglobulin G from rabbits immunized with CRPV VLPs protected against CRPV challenge. We conclude that native VLPs can induce antibody-mediated, type-specific protection against experimental papillomavirus infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7745754      PMCID: PMC189126          DOI: 10.1128/JVI.69.6.3959-3963.1995

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Antitumor immunity in the Shope papilloma-carcinoma complex of rabbits. I. Papilloma regression induced by homologous and autologous tissue vaccines.

Authors:  C A EVANS; L R GORMAN; Y ITO; R S WEISER
Journal:  J Natl Cancer Inst       Date:  1962-08       Impact factor: 13.506

2.  Structural polypeptides of rabbit, bovine, and human papillomaviruses.

Authors:  M Favre
Journal:  J Virol       Date:  1975-05       Impact factor: 5.103

Review 3.  Role of the human papillomavirus oncoproteins in transformation and carcinogenic progression.

Authors:  B A Werness; K Münger; P M Howley
Journal:  Important Adv Oncol       Date:  1991

Review 4.  Immune response to genital papillomavirus infections in women. Prospects for the development of a vaccine against cervical cancer.

Authors:  L Gissmann; I Jochmus; I Nindl; M Müller
Journal:  Ann N Y Acad Sci       Date:  1993-08-12       Impact factor: 5.691

5.  Evidence for antigenic determinants shared by the structural polypeptides of (Shope) rabbit papillomavirus and human papillomavirus type 1.

Authors:  G Orth; F Breitburd; M Favre
Journal:  Virology       Date:  1978-12       Impact factor: 3.616

Review 6.  The Shope papilloma-carcinoma complex of rabbits: a model system of neoplastic progression and spontaneous regression.

Authors:  J W Kreider; G L Bartlett
Journal:  Adv Cancer Res       Date:  1981       Impact factor: 6.242

7.  Antitumor immunity in the Shope papilloma-carcinoma complex of rabbits. 3. Response to reinfection with viral nucleic acid.

Authors:  C A Evans; Y Ito
Journal:  J Natl Cancer Inst       Date:  1966-06       Impact factor: 13.506

8.  Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles.

Authors:  R Kirnbauer; J Taub; H Greenstone; R Roden; M Dürst; L Gissmann; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

Review 9.  Prospects for cervical cancer vaccines.

Authors:  L Crawford
Journal:  Cancer Surv       Date:  1993

10.  A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.

Authors:  R Kirnbauer; N L Hubbert; C M Wheeler; T M Becker; D R Lowy; J T Schiller
Journal:  J Natl Cancer Inst       Date:  1994-04-06       Impact factor: 13.506

View more
  170 in total

1.  DNA-induced structural changes in the papillomavirus capsid.

Authors:  C Fligge; F Schäfer; H C Selinka; C Sapp; M Sapp
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 2.  Human papillomavirus therapy for the prevention and treatment of cervical cancer.

Authors:  Samir N Khleif
Journal:  Curr Treat Options Oncol       Date:  2003-04

3.  Development of bead-based immunoassay to quantify neutralizing antibody for human papillomavirus 16 and 18.

Authors:  Hai-Bo Liu; Pankaj Kumar Chaturvedi; Gantumur Battogtokh; Hyo Joo Bang; In-Wook Kim; Yong-Wan Kim; Kye-Shin Park; Woong Shick Ahn
Journal:  Mol Biotechnol       Date:  2013-06       Impact factor: 2.695

4.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

5.  Does human papillomavirus cause pterygium?

Authors:  T W Reid; N Dushku
Journal:  Br J Ophthalmol       Date:  2003-07       Impact factor: 4.638

6.  Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.

Authors:  Subhashini Jagu; Kihyuck Kwak; Robert L Garcea; Richard B S Roden
Journal:  Vaccine       Date:  2010-04-29       Impact factor: 3.641

Review 7.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

8.  Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease.

Authors:  Jon D Reuter; Beatriz E Vivas-Gonzalez; Daniel Gomez; Jean H Wilson; Janet L Brandsma; Heather L Greenstone; John K Rose; Anjeanette Roberts
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.

Authors:  Ratish Gambhira; Subhashini Jagu; Balasubramanyam Karanam; Patti E Gravitt; Timothy D Culp; Neil D Christensen; Richard B S Roden
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

Review 10.  Cervical cancer screening.

Authors:  Dorothy J Wiley; Bradley J Monk; Emmanuel Masongsong; Kristina Morgan
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.